Option chain shows key data for Sandoz Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sandoz Group.

Sandoz Group (OTC:SDZXF) Stock, Option Chain

Sandoz Group

Overview

News

Short Interest

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Comments

Sandoz Group Option Chain

No option chain data available. Please try again later